TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01564576

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)
Description: Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)
Description: Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
Study: NCT00631943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin (Lyrica)
Description: Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
Study: NCT03214666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTB-3550 TriKE® Phase I
Description: The 1st two patients will be assigned Dose Level 1. The study statistician will assign each new cohort of 2 patients to the most appropriate dose level based on updated toxicity probabilities.~* Dose Level 1 - 5 μg/kg/day~* Dose Level 2 - 10 μg/kg/day~* Dose Level 3 - 25 μg/kg/day~* Dose Level 4 - 50 μg/kg/day~* Dose Level 5 - 100 μg/kg/day~* Dose Level 6 - 150 μg/kg/day~* Dose Level 7 - 200 μg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTB-3550 TriKE® Phase II
Description: Patients will receive the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
Study: NCT02474069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Study: NCT02411890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block (active)
Description: adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block (active)
Description: femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (sham block)
Description: 30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block (sham block)
Description: 30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
Study: NCT04578236

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg
Description: Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Drug: Standard treatment Standard treatment
Description: Drug: Standard treatment Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study: NCT03336112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (I-CBT)
Description: The intervention (I-CBT) will consist of 5 weeks of Internet-delivered cognitive behavioral therapy using three main parts. The first is psychoeducation that aims to educate the patients about chest pain and other causes than the cardiac ones. The other part concerns avoidance and exposure. This includes exposing the patients to physical activities that patients perceive as a threat to the heart. The third part contains awareness (mindfulness) training to teach the patients to have contact with the present moment despite chest pain and not trying to avoid it.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information program
Description: Information program delivered by the Internet during 5 weeks.
Study: NCT02003599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
Study: NCT00299169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: N of 1 Trials
Description: N of 1 Trials of statin therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: N of 1 Trials
Description: N of 1 Trials of statin therapy
Study: NCT05454917

Intervention type: DEVICE
Intervention: Measure of ventilation/perfusion (V/Q) mismatch using Beacon ALPE (Automatic Lung Paramether Estimator)
Description: Evaluation of intraoperative V/Q mismatch using the Beacon ALPE during anesthesia.
Study: NCT04310371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention
Description: Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.~There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.
Study: NCT01995188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin fixed dose of AUC=6 mg/mL\*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin fixed dose of AUC=6 mg/mL\*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin fixed dose of AUC=6 mg/mL\*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNIB0600A
Description: DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNIB0600A
Description: DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNIB0600A
Description: DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNIB0600A
Description: DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
Study: NCT03862911

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: palliative radiotherapy
Description: Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Patients in this arm should not receive stereotactic doses or radiotherapy boosts. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: Lung: Tumors 5 cm or less surrounded by lung parenchyma 48 Gy/4#, or 54 Gy/3#, daily or every second day Within 2 cm of mediastinum or brachial plexus 60 Gy/8#, daily~Bone: Any bone 35 Gy/5#, or 24 Gy/2#, daily~Brain: Stereotactic lesions (no whole brain RT) \<2cm 20-24 Gy/1#, once 2-3 cm 18 Gy/1#, once Metastases only: 35Gy/5# to PTV, daily Whole brain + Mets: 35Gy to metastases, daily 20 Gy whole brain, daily~Liver: 54 Gy/3#, every second day~Adrenal/Pancreas: 40 Gy/5# / 35Gy/7#, daily~Lymph Node: 40 Gy/5#, daily
Study: NCT03832049

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
Description: 0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
Description: 0.5mL intramuscular dose - 2 doses (0 and 6 months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
Description: 0.5mL intramuscular dose - 2 doses (0 and 6 months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
Description: 0.5mL intramuscular dose - 1 doses (0 months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
Description: 0.5mL intramuscular dose - 1 doses (0 months)
Study: NCT01538667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
Study: NCT02575690

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Individuals receive 2 g of spirulina daily, for 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals receive a placebo daily, for 3 months.
Study: NCT05008406

Intervention type: OTHER
Intervention: Satisfaction
Description: Students Satisfaction

Intervention type: OTHER
Intervention: Satisfaction
Description: Students Satisfaction
Study: NCT00330967

Intervention type: DRUG
Intervention: 20% Intralipid
Description: lipid infusion

Intervention type: DRUG
Intervention: 20% Intralipid
Description: lipid infusion
Study: NCT02439502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuse® system
Description: Fuse® system will be used to perform gastro and endoscopic diagnostic procedures for upper and lower GI tract.
Study: NCT02236936

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard care of parenteral nutrition
Description: Standard treatment according to the discretion of the center, any required nutritional support (enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy) when considered necessary is allowed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Parenteral over night nutrition
Description: Patients in interventional Arm B will receive parenteral overnight nutrition with ZentroOLIMEL® 5.7% with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) starting with 15 ml/kg body weight/day. In case of weight loss of more than 5%, dose of ZentroOLIMEL® has to be increased up to 25 ml/kg/body weight/day.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Weekly during radiotherapy; not given if cisplatin is given during radiotherapy~Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Weekly during radiotherapy; not given if cisplatin is given during radiotherapy~Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin total dose of \>200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin total dose of \>200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 70 Gy / 5 fractions per week, over 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 70 Gy / 5 fractions per week, over 7 weeks
Study: NCT01419288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Description: The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
Study: NCT00922012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Stimulation Therapy
Description: Electromagnetic Stimulation Therapy for 24 weeks
Study: NCT01098513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 formulation AP
Description: GSK1349572 50 mg single dose fasted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 formulation AW
Description: GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 formulation AW
Description: GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 formulation AX
Description: GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 formulation AX
Description: GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B
Study: NCT01632618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trunk Muscle Training+NMES
Description: Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive control intervention
Description: Passive physical therapy approach to low back pain
Study: NCT03962504

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: trauma-focused treatment
Description: cognitive behavioral treatment for posttraumatic stress disorder that consists of exposure to the trauma memory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: trauma-focused treatment
Description: cognitive behavioral treatment for posttraumatic stress disorder that consists of exposure to the trauma memory.
Study: NCT00845117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultivated limbal stem cell graft transplantation
Description: A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
Study: NCT00035932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + ritonavir + tenofovir + nucleoside
Description: Active Comparator, Capsules, tablets, Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + saquinavir + tenofovir + nucleoside
Description: Active Comparator, Capsules, tablets, Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir + tenofovir + nucleoside
Description: Active Comparator, Capsules, tablets, Oral
Study: NCT01780220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
Study: NCT04292418

Intervention type: DRUG
Intervention: Tacrolimus capsule , mycophenolic acid
Description: measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2

Intervention type: DRUG
Intervention: Tacrolimus capsule , mycophenolic acid
Description: measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2
Study: NCT02752282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anticipatory Counseling
Description: Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cancer Screening Guidelines
Description: Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines
Study: NCT02356861

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on
Description: The LED helmet from Photomedex, Montgomeryville, PA will be used.~18 LED pods are in the helmet. Each LED pod:~Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2~20 NIR diodes, 830 nm and 4 red diodes, 633 nm.~1 J/cm2 = 30.4 sec

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on
Description: The LED helmet from Photomedex, Montgomeryville, PA will be used.~18 LED pods are in the helmet. Each LED pod:~Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2~20 NIR diodes, 830 nm and 4 red diodes, 633 nm.~1 J/cm2 = 30.4 sec
Study: NCT02233361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: A randomized controlled design will determine whether hearing aid users who are informed in advance of a follow-up appointment have a different pattern of hearing aid use than a control group that is not preinformed in advance.